Chlorprothixene

CHEMBL908 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

315.9 g/mol

LogP

5.2

Phase

4

A thioxanthene-class typical antipsychotic that blocks dopamine, histamine, adrenergic, and muscarinic receptors, used to treat schizophrenia and acute psychosis. It has marked sedative properties that can also be utilized for agitation and anxiety in certain settings. Extrapyramidal side effects and tardive dyskinesia are risks with long-term use.

Molekularmasse

315,9000 g/mol

LogP

5,20

TPSA

28,50 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Obesity

Wirkmechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21

InChI

InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-

Molecular Formula

C18H18ClNS

HBD / HBA

- / 2

Rotierbare Bindungen

3

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A thioxanthene-class typical antipsychotic that blocks dopamine, histamine, adrenergic, and muscarinic receptors, used to treat schizophrenia and acute psychosis. It has marked sedative properties that can also be utilized for agitation and anxiety in certain settings. Extrapyramidal side effects and tardive dyskinesia are risks with long-term use.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Chlorprothixene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL908. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 667467. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Chlorprothixene auf PillFYI

Struktur

Schnelldaten

Formel: C18H18ClNS

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.